Bessemer Group
JUNO

Bessemer Group’s Juno Therapeutics, Inc. JUNO Stock Holding History

Bessemer Group’s Portfolio JUNO Stock Details JUNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-351
Closed -$16K – 1890
2017
Q3 		$16K Hold
351
– – ﹤0.01% 1535
2017
Q2 		$10K Buy
+351
New +$8.66K ﹤0.01% 1601
2016
Q3 		– Sell
-3,809
Closed -$146K – 1913
2016
Q2 		$146K Hold
3,809
– – ﹤0.01% 712
2016
Q1 		$145K Hold
3,809
– – ﹤0.01% 723
2015
Q4 		$167K Buy
+3,809
New +$189K ﹤0.01% 764

Other funds holding JUNO

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Bessemer Group's JUNO Position: Q4 2017 in Review

Bessemer Group sold out of Juno Therapeutics, Inc. (JUNO) in Q4 2017, closing a stake of 351 shares — an estimated $16K sold.

Bessemer Group first reported a position in JUNO in Q4 2015 and held it in 5 quarters. The position peaked at $167K in Q4 2015. 237 funds tracked by Wall St. Rank hold JUNO as of Q4 2017.

  • Bessemer Group reported no remaining Juno Therapeutics, Inc. position as of Q4 2017 after selling out during the quarter.
  • Bessemer Group sold 351 Juno Therapeutics, Inc. shares in Q4 2017, an estimated $16K.
  • Bessemer Group first reported a position in Juno Therapeutics, Inc. in Q4 2015 and held it in 5 quarters.
  • Bessemer Group's Juno Therapeutics, Inc. position peaked at $167K in Q4 2015.
  • 237 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q4 2017.

Based on Bessemer Group's 13F filing for Q4 2017, filed 30 Jan 2018.